BRIM closes a $45.8 million rights issue early to accelerate its pipeline of regenerative peptides
Taipei, Taiwan, 13th September 2023 / Sciad Newswire / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company focusing on developing regenerative peptides for ophthalmology and degenerative joint diseases, announced today that 22,500 shares have been issued at a…
Taiwan has ambitions to make biotech ‘second industry’ after semi-conductors
Taiwan is looking to emulate Switzerland and become a prominent player in life sciences despite its relatively small size. In an interview at BIO International Convention 2023 in Boston, Yi-Chun Maria Chen, Vice President of Business Development at BRIM Biotechnology,…
BRIM plans to launch a new funding round to accelerate late-stage clinical trial and initiate a new phase 2 trial for orphan drug BRM424 in the U.S
Taipei, Taiwan, 9th May, 2023, BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company focusing on developing regenerative peptides for ophthalmology and degenerative joint diseases, announced today that the Board of Directors has approved a seasoned equity offering that…
BRM421, a new drug for treating Dry Eye Disease, receives approval to proceed to Phase 2 clinical trials in China
Taipei, Taiwan, 18th April 2023, BRIM Biotechnology, Inc. (“BRIM”, TPEx 6885) announced that BRM421 for the treatment of dry eye disease, licensed out to Grand Pharmaceutical Group Limited (Grand Pharmaceutical) for the China region, has been approved by the China…
BRIM submits US IND for BRM424 Phase 2 study treating neurotrophic keratitis
Taipei, Taiwan, 6th April 2023, BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative peptide therapies, submitted IND today for BRM424, which received ODD status from the FDA last November. If no comment from the FDA is…
BRIM Biotechnology announces first patient enrollment in pivotal Phase 3 clinical trial of BRM421 for Dry Eye Disease
Taipei, Taiwan, 2nd March 2023 / BRIM Biotechnology Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that the first patient has been enrolled in its Phase 3 clinical…
Novel regenerative peptide therapy for dry eye disease, BRM421, advances to Phase 3 clinical trials
There is currently no cure for Dry Eye Disease. Existing treatments are often not enough to control discomfort for moderate to severe patients unless there is a way to further speed up the healing process. Through its multi-modal mechanism of…
BRIM Biotechnology strengthens leadership team in preparation for transformational year ahead
BRIM’s new Board of Directors elects Andrew Lin as the new Chairman of the Board and appoints Dr. Wen-Chyi Shyu as the new CEO Taipei, Taiwan, February 20th, 2023 / BRIM Biotechnology, Inc. (BRIM, TPEx 6885), a clinical-stage company developing novel regenerative therapies…
BRIM Biotechnology receives FDA Orphan Drug Designation for BRM424 to treat neurotrophic keratitis
Taipei, Taiwan, 8th December 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye…
BRIM Biotechnology, Inc. raises $20 million in Series E funding round
Taipei, Taiwan, 1st December 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that it has raised $20 million in its Series E funding…